The additional (post hoc) analysis of results from Silence’s Phase II trial of Atu027 in pancreatic cancer is encouraging. We look forward to more comprehensive efficacy data from a larger Phase II prospective trial, which is due to commence over the next 18 months following completion of preclinical dose optimisation work.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Trial update
Silence Therapeutics plc (SLNCF:OTC) | 0 0 0.0%
- Published:
01 Jun 2015 -
Author:
Dr Jens Lindqvist -
Pages:
3
The additional (post hoc) analysis of results from Silence’s Phase II trial of Atu027 in pancreatic cancer is encouraging. We look forward to more comprehensive efficacy data from a larger Phase II prospective trial, which is due to commence over the next 18 months following completion of preclinical dose optimisation work.